Health insurance benefit of severe COPD drugs expanded

The health insurance benefit standard of ‘Daxas,’ an oral COPD treatment, is anticipated to be expanded.

According to the industry concerned on the 14^th, the Health Insurance Review & Assessment Service(HIRA) is currently reviewing expansion of health insurance benefits for severe COPD(Chronic Obstructive Pulmonary Disease) drugs such as Daxas(roflumilast), a PDE4 inhibitor.

If they get a pos...